美国新冠疫情初期多中心COVID-19药物治疗利用与安全性的点患病率评估
该研究为美国15家医院开展的非干预性多中心点患病率研究,纳入2020年4月18日至5月8日住院的352例疑似/确诊COVID-19患者。19%患者接受靶向药物治疗,其中羟氯喹占69%;接受药物治疗者中12%发生药物不良反应,临床试验入组者ADR报告率更高(62.5% vs 22%,OR 5.9,P=0.028)。
要点
- COVID-19靶向药物治疗率19%,羟氯喹占69%、瑞德西韦10%、IL-6拮抗剂9%。
- 接受药物治疗者中12%发生药物不良反应。
- 临床试验入组者ADR报告率更高(62.5% vs 22%,OR 5.9,P=0.028)。
核心结论
- COVID-19患者支持治疗率高,但接受药物治疗者药物不良反应常见,包括临床试验入组患者。
- 需要综合系统来识别和减轻实验性COVID-19治疗相关的不良反应。
研究设计与样本
- 非干预性、多中心、点患病率研究,评估住院疑似/确诊COVID-19患者24小时窗内的临床与治疗特征。
- 纳入2020年4月18日至5月8日美国15家医院的352例COVID-19治疗患者,每中心随机抽取至多30例。
主要发现
- 有哮喘史者靶向药物使用率高于无哮喘史者(14.9% vs 7%,P=0.037)。
- 临床试验入组者靶向药物使用率高于非入组者(26.9% vs 3.2%,P<0.001)。
- 接受药物治疗者中8例(12%)发生ADR;临床试验入组者ADR报告率更高(62.5% vs 22%;OR 5.9;P=0.028)。
临床怎么用
- 临床药师应关注COVID-19实验性治疗药物的不良反应监测,尤其对临床试验入组患者加强药学监护。
局限性
- 点患病率设计仅评估24小时窗内特征,可能低估治疗全程的不良反应。
- 研究为观察性设计,无法推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients. PURPOSE: There are currently no FDA-approved medications for the treatment of coronavirus disease 2019 (COVID-19). At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period. METHODS: We conducted a noninterventional, multicenter, point prevalence study of patients hospitalized with suspected/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19-targeted therapies. The secondary objective was to describe adverse drug reactions (ADRs). RESULTS: A total of 352 patients treated for COVID-19 at 15 US hospitals From April 18 to May 8, 2020, were included in the study. Most patients were treated at academic medical centers (53.4%) or community hospitals (42.6%). Sixty-seven patients (19%) were receiving drug therapy in addition to supportive care. Drug therapies used included hydroxychloroquine (69%), remdesivir (10%), and interleukin-6 antagonists (9%). Five patients (7.5%) were receiving combination therapy. The rate of use of COVID-19-directed drug therapy was higher in patients with vs patients without a history of asthma (14.9% vs 7%, P = 0.037) and in patients enrolled in clinical trials (26.9% vs 3.2%, P < 0.001). Among those receiving drug therapy, 8 patients (12%) experienced an ADR, and ADRs were recognized at a higher rate in patients enrolled in clinical trials (62.5% vs 22%; odds ratio, 5.9; P = 0.028). CONCLUSION: While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy, including those enrolled in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 treatments.
引用
- Rhodes NJ, Dairem A, Moore WJ, et al. Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. Am J Health Syst Pharm. 2021. PMID: 33537767. doi:10.1093/ajhp/zxaa426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。